Management of early viable cervical pregnancy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 15777436.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate conservative management of early viable cervical pregnancy. Prospective study. A tertiary teaching hospital. All cases of cervical pregnancies with fetal cardiac activity presenting to our hospital over six years. All cases were managed with trans-abdominal intra-amniotic injection of 25 mg of methotrexate under ultrasound guidance. Follow up sonographic examinations and serum beta-hCG measurements were performed every three days. Cervical curettage was performed after two follow up ultrasound examinations had shown a dead fetus and a regressing gestational sac as well as declining beta-hCG levels. Patients were managed as outpatients. Successful management and need for hospitalisation. Nine cases were encountered. Two required a second injection of methotrexate for persistent fetal cardiac activity and serum beta-hCG rise in the follow up examination. We did not observe any side effects and no patient required admission to the hospital. Intra-amniotic methotrexate injection and subsequent cervical curettage after one week is a successful alternative for the management of cervical pregnancies.
Medical subject headings
- Abortifacient Agents, Nonsteroidal
- Abortion, Therapeutic
- Curettage
- Methotrexate
- Pregnancy, Ectopic